6-K
Novo Nordisk A S (NVO)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 12, 2026
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
|---|
Trading in Novo Nordisk shares by boardmembers, executives and associated persons
Bagsværd, Denmark, 12 May 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
|---|---|---|---|---|
| a) | Name of the Board member/Executive/Associated<br> Person | Caroline Munk<br> Esbjerg | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Closely associated<br> person to Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer (CFO) | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3 | Details of the issuer | |||
| a) | Name | Novo Nordisk<br> A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details of the transaction(s) | |||
| a) | Description of the financial instrument,<br>type of instrument, | Shares | ||
| Identification code | Novo Nordisk<br> B DK0062498333 | |||
| b) | Nature of the transaction | Shares received<br> as gift | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| DKK 294.30 | 50 | |||
| d) | Aggregated<br> information<br> <ul><br> <li>Aggregated volume</li><br> <li>Price</li></ul> | 50<br> shares<br>DKK 14,715 | ||
| e) | Date of the transaction | 2026-05-07 | ||
| f) | Place of the transaction | Outside a<br> trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
|---|---|---|---|---|
| a) | Name of the Board member/Executive/Associated<br> Person | Sofie Munk<br> Esbjerg | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Closely associated<br> person to Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer (CFO) | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3 | Details of the issuer | |||
| a) | Name | Novo Nordisk<br> A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details of the transaction(s) | |||
| a) | Description of the financial instrument,<br>type of instrument, | Shares | ||
| Identification code | Novo Nordisk<br> B DK0062498333 | |||
| b) | Nature of the transaction | Shares received<br> as gift | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| DKK 294.25 | 50 | |||
| d) | Aggregated<br> information<br> <ul><br> <li>Aggregated volume</li><br> <li>Price</li></ul> | 50<br> shares<br>DKK 14,712.50 | ||
| e) | Date of the transaction | 2026-05-07 | ||
| f) | Place of the transaction | Outside a<br> trading venue |
About Novo Nordisk
Novo Nordisk is a leading global healthcarecompany founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon ourheritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent andultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. Formore information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube
Contacts for further information
| Media: | |
|---|---|
| Ambre James-Brown | Liz Skrbkova (US) |
| +45 3079 9289 | +1 609 917 0632 |
| [email protected] | [email protected] |
| Investors: | **** |
| Michael Novod | Jacob Martin Wiborg Rode |
| +45 3075 6050 | +45 3075 5956 |
| [email protected] | [email protected] |
| Max Ung | Sina Meyer |
| +45 3077 6414 | +45 3079 6656 |
| [email protected] | [email protected] |
| Alex Bruce | Christoffer Sho Togo Tullin |
| +45 3444 2613 | +45 3079 1471 |
| [email protected] | [email protected] |
| Mads Berner Bruun | Frederik Taylor Pitter |
| +45 3075 2936 | +1 609 613 0568 |
| [email protected] | [email protected] |
| Novo Nordisk A/S<br><br>Investor Relations | Novo Allé 1<br><br>2880 Bagsværd<br><br>Denmark | Telephone:<br><br>+45 4444 8888 | www.novonordisk.com<br> CVR no: 24 25 67 90 |
|---|---|---|---|
| Company<br> announcement No 31/ 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: May 12, 2026 | NOVO NORDISK A/S<br><br> <br><br><br> <br>Maziar Mike Doustdar<br><br> <br>Chief Executive Officer |
|---|